SynAct Pharma AB (SE0008241491) — research page
SE · se-cm-kg/XSTO/SE0008241491 · as of 2026-11-06
Identity and listing
The issuer is SynAct Pharma AB, listed on Nasdaq Stockholm, with ticker SE0008241491, ISIN SE0008241491 and LEI 549300RRYIEFEQ72N546. The security type, segment, sector and jurisdiction are not on the record. Its listing status is listed, not halted.
| field | value | source · read date |
|---|---|---|
| name | SynAct Pharma AB | source · 2026-11-06 |
| exchange | Nasdaq Stockholm | source · 2026-11-06 |
| ticker | SE0008241491 | source · 2026-11-06 |
| ISIN | SE0008241491 | source · 2026-11-06 |
| LEI | 549300RRYIEFEQ72N546 | source · 2026-11-09 |
| security type | not on the record | |
| segment | not on the record | |
| sector | not on the record | |
| jurisdiction | not on the record | |
| status | listed, not halted | source · 2026-11-09 |
The disclosure read
The record holds 49 filings across 45 filing days in the window 2025-11-06 to 2026-11-06. The median gap between filing days is 7.5 days. The median latency from the latest filing to the record date is 7.0 days for the exchange, against 2 days for this issuer. The exchange median is 9.5 days for cadence and 30.0 filings for the window, across 398 issuers. The sector median is not on the record. The latest filing is an Investor News item dated 2026-11-04.
| filings | median gap between filing days | days from latest filing to as-of | |
|---|---|---|---|
| this issuer | 49 | 7.5 | 2 |
| exchange median: Nasdaq Stockholm (398 issuers) | 30 | 9.5 | 7 |
| date | type | category | filing |
|---|---|---|---|
| 2026-11-04 | Investor News | Investor News | SynAct Pharma announces attendance and presentation at upcoming investor conferences |
| 2026-11-03 | Interim report (Q1 and Q3) | Interim report (Q1 and Q3) | SynAct Pharma publishes Q3 2026 interim results |
| 2026-11-03 | Investor News | Investor News | SynAct Pharma announces initiation of coverage by BioVal BioStock Analytics |
| 2026-10-27 | Investor News | Investor News | SynAct Pharma signs first commercial partnership for resomelagon with leading Brazilian pharmaceutical company |
| 2026-09-22 | Investor News | Investor News | SynAct Pharma to participate in investor and partnering conferences |
window 2025-11-06 to 2026-11-06 · the node's disclosure lines, as get_filings serves them
Auditor
The auditor and its location are not on the record. Auditor changes are not on the record.
Events and halts
The listing, delisting, name change, domicile change and segment move lines are not on the record, because the index carries no lifecycle type map for this register. The halt flag is listed, not halted.
Orderability
The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/se/mifid-ii-product-governance/r1.
rule acm-68000/se/mifid-ii-product-governance/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability
Coverage
Two research houses are named on the issuer's investor-relations page: Edison Investment Research and BioVal BioStock Analytics.
| research house | analyst | source · read date |
|---|---|---|
| Edison Investment Research | Jyoti Prakash, CFA and Dr Arron Aatkar | issuer page · 2026-11-12 |
| BioVal BioStock Analytics | Hanna Norrlid, BioStock Analytics | issuer page · 2026-11-12 |
Open research
One openly published research note is on the record: Edison Investment Research, dated 2025-10-28.
| date | publisher | note | kind |
|---|---|---|---|
| 2025-10-28 | Edison Investment Research | SynAct Pharma – Differentiated inflammation resolution approach | issuer-sponsored |
Licensed
Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.
| licensor | entitlement | title | date | source |
|---|---|---|---|---|
| none loaded |
As-of depth
The market's vintage is not sealed. No issuer years are sealed, and the market's earliest sealed date and the live record start date are not on the record.
Sources
8 source pages are named on this page; every value above carries its own source page and read date in the numbers.
- 10.1
- https://firds.esma.europa.eu/firds/ (identity.exchange)
- 10.2
- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)
- 10.3
- https://mcp.se-cm-kg.ai/events/XSTO/SE0008241491 (the disclosure lines)
- 10.4
- https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation (the halt flag)
- 10.5
- https://se.eu-cm-kg.ai/book/aio.json (the orderability chapter)
- 10.6
- https://www.synactpharma.com/en/investors/analysts/ (coverage)
- 10.7
- https://www.edisongroup.com/research/differentiated-inflammation-resolution-approach/BM-2174/ (open research)
- 10.8
- https://mcp.se-cm-kg.ai/record/XSTO/SE0008241491 (the record)
Read it by agent
The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"isin":"SE0008241491"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:444cfeff1939c240.